Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.
Location: United States, New Jersey, Jersey City
Employees: 11-50
Total raised: $41M
Founded date: 2019
Investors 3
| Date | Name | Website |
| 17.05.2024 | LIFTT | liftt.com |
| - | Club degli... | clubdeglin... |
| - | NovaCapita... | novacapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.04.2024 | - | $26M | - |
| 15.03.2023 | Series B | $15M | - |
Mentions in press and media 15
| Date | Title | Description |
| 28.01.2025 | Lantheus to Acquire Evergreen Theragnostics to Expand Radiopharmaceutical Capabilities | What You Should Know: – Lantheus Holdings, Inc., a radiopharmaceutical company, announced today a definitive agreement to acquire Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company. – The all-cash transaction consis... |
| 21.05.2024 | Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer | SPRINGFIELD, N.J., May 21, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced that they have entered into a collaboration and licensing-agreement with the Medical University of ... |
| 18.04.2024 | Evergreen Theragnostics Secures $26M to Drive Radiopharmaceutical Innovation | Evergreen Theragnostics, a cutting-edge radiopharmaceutical company based in Springfield, NJ, has successfully completed a $26M capital raise, with support from Petrichor and LIFTT. This funding will propel the company's groundbreaking rese... |
| 16.04.2024 | Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Servic... | SPRINGFIELD, N.J., April 16, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new... |
| 16.04.2024 | Evergreen Theragnostics Completes $26M Funding | Evergreen Theragnostics, a Springfield, NJ-based clinical-stage radiopharmaceutical company, raised $26M in funding. Backers included Petrichor and LIFTT. The company intends to use the funds to expand operations and its R&D sector. Led... |
| 16.04.2024 | Evergreen Theragnostics Lands $26M | SPRINGFIELD, NJ, Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26 million capital raise. >> Click here for more funding data on Evergreen Theragnostics >>... |
| 15.03.2023 | Evergreen Theragnostics Closes $15M Series B Funding | Evergreen Theragnostics, a Springfield, NJ-based clinical stage contract development and manufacturing organization (CDMO), raised $15M in Series B funding. The backers were nor disclosed. The company intends to use the funds to prepare for... |
| 13.03.2023 | Evergreen Theragnostics Nets $15M Series B | SPRINGFIELD, NJ, Evergreen Theragnostics, a clinical stage contract development and manufacturing organization, announced the completion of a $15M Series B. >> Click here for more funding data on Evergreen Theragnostics >> T... |
| 30.09.2021 | Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials | SYDNEY, Sept. 30, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and... |
| 15.07.2021 | Evergreen Theragnostics Expands Alpha Radiopharmaceutical Production Capabilities |
Show more